|
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) announced today that researchers at The University of Texas Southwestern Medical Center at Dallas (UT Southwestern) presented pre-clinical data at the American Association of Cancer Research annual meeting demonstrating that its anti-phospholipid antibody 3G4 significantly enhances the efficacy of chemotherapy.
In data presented breast cancer tumors were treated with a combination of 3G4 and Docetaxel (Taxotere(R)) which is among the most widely used chemotherapy agents to treat breast cancer. Combination therapy with 3G4 and Docetaxel resulted in 93% inhibition of human breast cancer growth in pre-clinical models. Peregrine has developed a chimeric 3G4 analog that it is developing under the trade name Tarvacin®. Tarvacin is part of Peregrine’s Vascular Targeting Agent Anti-Phospholipid Therapy (APT) program and is expected to enter human clinical studies later this year.
In the study the authors evaluated the effectiveness of 3G4 to enhance the therapeutic effect of Docetaxel in breast tumor models. Tumor growth was inhibited by 93% in the combination treated group as compared with 68% and 60% in groups treated with Docetaxel or 3G4 alone respectively. The authors concluded “These studies indicate that as an adjuvant therapy 3G4 could enhance the therapeutic efficacy of Docetaxel in breast cancer patients potentially providing a more effective therapy for breast cancer.�
|
Linear Mode
